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Introduction
Multiple sclerosis (MS) is a chronic inflammatory neurological 
disease of the central nervous system; characterized by demyelination, 
neurodegeneration and astroglial proliferation [1], with complex 
genetic factors exerting a profound influence [2]. Despite major 
advances in the current understanding of the pathogenesis of MS, the 
inflammatory cascade involved in MS remains unknown; although there 
is considerable evidence implicating the involvement of mitochondria 
DNA mutations involved in axonal and glial injury mechanisms [3-
5]. Mitochondrial dysfunction in microglial cells has been observed in 
several animal models of neurodegeneration and aging, in this regard 
the mitochondrial DNA damage in particular is most pronounced 
within microglial cells, especially compared to neurons [6]. There is 
currently no treatment for the loss of neuronal function after damage 
to the nervous system, multiple attempts at nerve re-growth across 
the peripheral nervous system (PNS) and (CNS) transition have not 
been successful [7]. Injuries and neurodegenerative (ND) diseases of 
the central nervous system (CNS), like MS are unique in that they 
almost always get repaired by gliosis leading to loss of neurological 
function and resultant neurological deficits in the affected individual. 
Widespread microglial activation is a histopathological hallmark of 
progressive MS and inhibition of this aspect of innate immunity could 
potentially have beneficial effects on both progressive and relapsing 
forms of MS [8]. Majority of ND, including (MS) is characterized by 
activation of microglia and mitochondrial dysfunction in microglial 
cells are thought to contribute to the harmful effects neuroinflammation 
seen in these diseases [6]. One of the most distressing aspects of MS 
treatment is the failure of development of disease-modifying therapies 
that slow disability in progressive forms of MS. At present, none of the 
drugs do attempt to reduce the inflammatory process and target either 
the primary progressive or secondary progressive MS [8]. Very trivial 
studies in animal models have come up in the field of cell therapy as a 
treatment modality for this demyelinating disease.
Current Scenarios in the Drug Management of Multiple 
Sclerosis
As a result of the past 20 years of research done for treatment 
of MS, various forms of auto injectable interferon beta (IFN b) and 
Glatiramer acetate (GA) got into the market with GA 40 mg given 
subcutaneously reduced the relapse rate at 1 year [9] and became 
widely used as first line disease treatments. Natalizumab, and to a much 
lesser extent Mitoxantrone, are second-line intravenously infused 
treatments. With teriflunomide in patients with relapsing MS study 
showed teriflunomide’s clinical efficacy in reducing the relapse rate 
and neurological deficits in MS over a period of 2 years [10]. Several 
phase III studies in relapsing MS are ongoing for second-generation 
sphingosine-1-phosphate receptor 1 immunomodulators which show 
promise in reducing some of the side effects associated with such an 
agent like bradycardia, abnormal hepatic enzyme elevations, and lung 
fibrosis [8]. Vitamin D deficiency has been recently identified as a 
risk factor and its potential in the possible disease modifying role and 
awaits clinical trials in the relapsing MS [11]. 
Current Status of Stem Cell Therapy in Multiple Sclerosis
In humans, neurogenesis largely ceases during adulthood, but in 
two areas of the brain, the hippocampus and olfactory bulb, there is 
strong evidence of regeneration of substantial numbers of new neurons 
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[12]. Studies done in detail on the use of (ESCs) in MS have revealed 
that the actual limitation is the preparation of sufficient human 
oligodendrocytes precursor cells in getting tissue-specific progenitor 
cells from human embryonic stem cells (ESCs) and the dangers that 
there are always risk of tumorogenesis in neural cells derived from 
ESCs, limiting the potentialities of science and therapy in such studies 
[13]. Another shortcoming of the autologous MSC and induced 
pluripotent stem cells (iPS), transplantation in the treatment of MS 
is that of carrying the inherited (mtDNA) mutation to the CNS. For 
MSC there is lingering doubt whether the MSC derived neurons are 
functional [14], and as similar fate could be expected if it ends up 
differentiating into a glia.
Recommendation for a Novel Cell Therapy in Multiple 
Sclerosis
From extensive reviews on the cell therapy methodologies it can 
be computed that partial successes or disappointments encountered 
in treating MS with autologous embryonic stem cell transplants have 
occurred due to immune rejection and/or persistence of inherited or 
acquired mutated mitochondrial DNA in the glial cells in the case of 
autologous iPS transplants. Although transplantation of Mesenchymal 
Stem Cell (MSC), or induced pluripotent stem (iPS) cells generated 
from autologous somatic OECs and reprogrammed into ES-like cells 
may provide an additional source of autologous stem cells for treating 
MS, both would be of no potential benefit as would continue to harbour 
the same mitochondrial mutations (mtDNA) as possessed by glia in 
CNS [15]. The field of mitochondrial-targeted therapeutics is one that 
is growing fast and is of great importance and an increasing evidence 
points towards mutation leading to altered mitochondrial trafficking 
and fusion-fission dynamics in several ND diseases including MS [16]. 
MS can be targeted for slowing down the progression, prevention of 
onset and possible treatment by perhaps by the proposed genetically 
modified glial cells cloned by somatic Nucleus Transfer (NT) of 
Olfactory ensheathing cells to a healthy donor oocyte devoid of 
mtDNA mutations. OECs normally perform regenerative, scavenging 
and innate immune functions in the olfactory region and have been 
investigated thoroughly in related to spinal cord injuries, amyotrophic 
lateral sclerosis and other ND diseases where research suggests that 
these cells possess a unique ability to remyelinate injured neurons [17]. 
A new strategy for isolating oligodendrocyte progenitor cells of the 
human brain may advance the goal of therapeutic remyelination [18].
Here we propose glia cloned with an autologous nuclear component 
of the recipient’s OEC’s, union by combination of whole somatic 
OECs with a healthy oocyte cytosol [15] (Figure 1), offers an alternate 
speculative likelihood of producing NT-derived ES cells in which 
mutated mtDNA is substantially diluted/destroyed by the mtDNA of 
oocyte as it does to the mitochondrial DNA of the spermatozoa, shortly 
after fertilization. The resulting inner cell mass from the blastocyst 
stage of development would become a source of induced pluripotent 
stem cells that would differentiate into a radial glia like OEC’s with the 
inherent properties of axonal and myelin generation and scavenging 
functions. Xenotranplantation of myelin-forming OEC’s from pigs 
genetically altered to reduce the hyperacute response in humans are 
able to induce elongative axonal regeneration and remyelination and 
restore impulse conduction across the transected spinal cord [19]. The 
transplantation of the proposed cells followed by the self-renewal of 
this ESC at sites of demyelination would attempt to repair the gliosis 
and dilute the activated microglia population that is the leading cause 
of defects seen in MS. 
Figure 1: Olfactory Mucosa (OM) and Olfactory Bulb (OB) contain Olfactory Ensheathing Cells (OECs). The single Somatic Nuclear Transfer (SCNT) to an enucleated 
Oocyte would develop into a blastocyst. The inner cell mass differentiating into radial microglia could be used for transplantation into the central nervous system in 
Multiple Sclerosis.
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After being reported that transplantation of heterologous fetal OECs 
into the frontal lobes it has been seen to slow down the rate of clinical 
progression in ALS patients, the subsequent neuropathologic analysis 
did not support a therapeutic efficacy for ALS patients even after OEC 
transplantation via the ventricles, although transplantation of OECs 
engineered to produce neurotrophins might be helpful to improve the 
condition in ALS [17]. Culturing and transplanting this cloned glia that 
expresses identical HLA antigens would not evoke an autoimmune 
rejection while the mitochondria’s of oocyte of a healthy donor 
would possibly dilute the activated microglia slow down the ongoing 
neuronal degeneration [6,15,16]. The additional rewarding benefit of 
such transplantation would be that the regenerative and scavenging 
potentials of OECs in contrast to the over reactive microglia present 
in the CNS of the MS patients, would help recover the damage already 
caused by the degenerative process, a feature missing in mesenchymal 
stem cells (MSC) and iPS. The use of the NT to develop isogenic ES 
cell-based therapies for the prevention and treatment of MS associated 
with mtDNA mutations may open a new avenue of designer’s targeted 
cell therapy unique for the patients with MS.
Weighing the Benefits Ahead of Transplantations
The nuclear profiling of the cloned glia by microarray for differential 
expression of mtDNA and nuclear DNA of these engineered cells 
prior to transplant would clearly highlight the benefits of the planned 
transplantation. A similar gene profiling of the patient's glial cells 
would help understand the differences in their  epigenetic expression 
and the gains of the procedure in the ongoing MS in the patients. Once 
evaluated and approved for transplant, these cloned cells like their 
parent OEC’s can be labelled and tracked by a magnetic resonance 
imaging (MRI) device when being dispersed in the CNS. A recent study 
has made use of a novel type of Micron-sized Particles of Iron Oxide 
(MPIO) to label and track these transport-mediated cells via MRI [20]. 
Novel Delivery via transcribrial route device
The advantage of transplantation techniques done in past via 
intrathecal, intraventricular, intra-parenchyma and several other 
routes can be considered for the aforementioned cloned glial cells. 
Methods of cells being delivered to CNS through an intranasal 
route has been reported in the past. The nasal route has therapeutic 
effects that appear to be equivalent to those induced by intravenous 
route adult neural stem cells (NSCs) and lead to protection from 
CNS inflammation and the promotion of remyelination and neural 
repair. Such an effective alternative route of administration could 
significantly improve the efficacy of NSC-based therapy in MS [21]. 
There is potential of this intranasal route principally for the therapy of 
neurodegenerative disorders, this delivery method provides the option 
of chronic treatment which may enhance the number of delivered cells 
in order to achieve therapeutic benefit [22].
We have recently proposed a “transcribrial route device” that is 
composed of three connected components [23] to access the brain across 
the criribriform plate of the ethimoid bone. This can be of advantage 
because of  being painless and the trimmed ball-valve terminal could 
prevent any regurgitation back into the delivery system. A local 
anaesthetic application prior to the cell therapy could minimize the 
reflex sneezing that is expected on insertion of the nasal components. 
Unlike other routes this route would clearly avoid the risks of escape of 
the cells into the lungs and various neurological complications of other 
cell therapy delivery systems.
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